Facebook Twitter

The Novavax COVID-19 vaccine is 90% effective. It could be available this fall

Novavax released new details about its COVID-19 vaccine Monday

SHARE The Novavax COVID-19 vaccine is 90% effective. It could be available this fall
A Phase 3 Novavax coronavirus vaccine trial.

In this Wednesday, Oct. 7, 2020, file photo, a Phase 3 Novavax coronavirus vaccine trial volunteer is given an injection at St George’s University hospital in London.

Alastair Grant, Associated Press

Novavax, a Biotech company, announced Monday that its COVID-19 vaccine is rather effective and that it plans to make it available sometime later this year.

How effective is Novavax’s vaccine?

The company said Monday that the two-dose COVID-19 vaccine is 90.4% effective, based on data from three clinical trials that included 30,000 participants, according to CNBC.

Moreover, the Novavax vaccine was shown to be 100% effective in stopping moderate and severe COVID-19.

Does it work against COVID-19 variants?

The two-dose vaccine is 93% effective against some COVID-19 variants, according to Novavax, specifically those of concern and interest. It did not mention specific variants.

In most cases, variants of concern include the alpha, beta, gamma and delta variants, which were discovered in the U.K., South Africa, Brazil and India, respectively, as the Deseret News reported.

A full list of variants of concern and interest can be found at the Centers for Disease Control and Prevention.

When will the Novavax vaccine be available?

Novavax said it plans to submit its vaccine for approval from the Food and Drug Administration in the third quarter of 2021.

Is this good news?

Dr. Gregory Glenn, Novavax’s president of research and development, said in a statement that the data proves the effectiveness of the vaccine.

  • “These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus. Our vaccine will be a critical part of the solution to COVID-19 and we are grateful to the study participants and trial staff who made this study possible, as well as our supporters, including the U.S. Government.”